Urologix(R), Inc. (Nasdaq:ULGX – News), the manufacturer and marketer of minimally invasive Cooled ThermoTherapy(TM) (CTT) for the treatment of BPH, announces the signing of an Exclusive Worldwide License for the Prostiva(R) RF Therapy System from Medtronic, Inc.(NYSE:MDT – News). Prostiva RF (Radio Frequency) Therapy is a transurethral needle ablation device that is 510(k) cleared for the treatment of BPH and is most commonly used in the urologist’s office.
The license agreement is for a 10-year term and includes the rights to manufacture and market the Prostiva product line in consideration for an upfront license fee and ongoing royalties. The combination of Prostiva RF Therapy with Cooled ThermoTherapy will allow Urologix to offer urologists a broad in-office BPH solution set and will expand Urologix’ addressable patient population.
Read entire article: http://finance.yahoo.com/news/Urologix-Announces-Signing-pz-2183449426.html?x=0&.v=1